• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [21797 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risankizumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risankizumab (plaque psoriasis) - Second Addendum to Commission A19-41]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risankizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risankizumab (plaque psoriasis) - Addendum to Commission A19-41]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risankizumab (Crohn’s disease) - Benefit assessment according to § 35a SGB V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risankizumab (Crohn disease) – Addendum to Commission A22-133]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ripretinib (gastrointestinal stromal tumour (GIST)) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020     National Committee for Technology Incorporation (CONITEC) [Riociguat for inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension after surgical treatment]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Riociguat (pulmonary arterial hypertension in children and adolescents) – Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Riociguat (PAH) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Riociguat (CTEPH) - Benefit assessment according to §35a Social Code Book V]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Riociguat - Assessment according to § 35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Riluzole in amyotrophic lateral sclerosis]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rilpivirine (new therapeutic indication): addendum to commisison A15-55]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rilpivirine (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rilpivirine (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rilpivirine - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2020     National Committee for Technology Incorporation (CONITEC) [Rifapentine plus isoniazid for treatment of latent mycobacterium tuberculosis infection (LTBI)]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ribociclib (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ribociclib (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ribociclib (breast cancer) - Addendum to Commission A17-45]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ribociclib (breast cancer; combination with fulvestrant) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ribociclib (breast cancer; combination with fulvestrant) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ribociclib (breast cancer; combination with fulvestrant) - Addendum to Commission A19-06]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ribociclib (breast cancer; combination with an aromatase inhibitor) - Addendum to Commission A19-06]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ribociclib (breast cancer, combination with fulvestrant) - Addendum to commission A20-22]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ribociclib (breast cancer, combination with an aromatase inhibitor) - Addendum to commission A20-21]
2002     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Rheumatoid arthritis - health technology assessment of diagnosis and treatment]
2011     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [ReWalk(tm): motorized orthosis in wheelchair users paraplegic people]
2010     Committee for New Health Technology Assessment (CNHTA) [Revolix 70]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Revision of the information materials on colorectal cancer screening]
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Review process of matricial requirements for acute care facilities in the Quebec traumatology network]
2007     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Review on the medical and health economic evidence for an inclusion of colposcopy in primary screening programs for cervical cancer]
2007     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Review on the medical and health economic evidence for an inclusion of colposcopy in primary screening programs for cervical cancer]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Review of the study protocol and statistical analysis plan on routine practice data collection for onasemnogene abeparvovec acc. to the Law for More Safety in the Supply of Medicines (GSAV) - Addendum to commission A20-61]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Review of the study protocol and statistical analysis plan on routine practice data collection for onasemnogene abeparvovec - Second addendum to Commission A20-61]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Review of the study protocol and statistical analysis plan on routine practice data collection for brexucabtagene autoleucel acc. to the Law for More Safety in the Supply of Medicines (GSAV) - Addendum to commission A21-130]
2010     Basque Office for Health Technology Assessment (OSTEBA) [Review of the psychological treatment in first psychotic episode]
2014     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Review of the indications of stereotactic body radiation therapy (SBRT) in patients with primary tumours and oligometastases]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Review of the final study protocol and statistical analysis plan on routine practice data collection for onasemnogene abeparvovec - Third addendum to Commission A20-61]
2021     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Review of the evidence on the impact of school closures through the evolution of the COVID-19 pandemic]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Review of the efficacy of drug treatment for neuropathic pain]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Review of the efficacy of drug treatment for neuropathic pain (2nd edition)]
2014     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Review of positron emission tomography (PET) indications. Appropriate use criteria]
2021     Center for Drug Evaluation (CDE) [Review of international guidelines and comparative effectiveness of high cost antidiabetes drugs]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Review of age limits in the mammography screening programme]
2009     National Evidence-based Healthcare Collaborating Agency (NECA) [Reuse of single-use medical devices: current evidence and regulations]
2009     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Reuse of single use medical devices]
2014     Basque Office for Health Technology Assessment (OSTEBA) [Retinal protection during eye surgery]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Retigabine - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Results of the perinatal care of very premature children in the health system of the Basque Country]
2010     Andalusian Health Technology Assessment Area (AETSA) [Results from endovascular treatment in lower limb peripheral arterial disease]
2011     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Responder analyses for memantine in Alzheimer's disease - Rapid report]
2008     Committee for New Health Technology Assessment (CNHTA) [Respiratory syncytial virus, RT-nested PCR]
2021     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Respiratory rehabilitation following hospitalization related to a diagnosis of COVID-19]
2022     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Respiratory rehabilitation following hospitalization related to a diagnosis of COVID-19 - an update]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Respiratory polygraphy for obstructive sleep apnea syndrome]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Reslizumab (severe eosinophilic asthma) - Benefit assessment according to § 35a Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Reslizumab (asthma) - Addendum to Commission A17-02]
2012     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Researchers' perceptions about the clinical and health services research call]
2010     National Evidence-based Healthcare Collaborating Agency (NECA) [Research on methodologies for evidence-based healthcare decision-making processes in Korea]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [Research on medical care utilization of stroke patients and related factors in Korea]
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [Research for extending the scope of health technology assessment (HTA): focusing on tobacco control]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Zemaira - congenital alpha1- antitrypsin deficiency]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Vistaseal™ – Intraoperative bleeding]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: validation of the management framework for a nonspecific human immunoglobulin shortage]
2017     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: use, in Québec, of probiotics in the prevention of Clostridium difficile-associated diarrhea in hospitalized patients on antibiotic therapy]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: use of the SpaceOAR hydrogel rectal spacer during prostate radiotherapy]
2018     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: use of the prostate-specific antigen (PSA) test in prostate cancer screening in Québec]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: use of single-photon emission computed tomography with [ 123I]ioflupane (DaTscan) in the diagnostic process for parkinsonian syndromes]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: use of platelet-rich plasma for the treatment of knee osteoarthritis]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: use of microsurgery for the prevention and treatment of cancer-related lymphedema]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: use of linear accelerators with on-board magnetic resonance imaging (MRI) for real-time MRI-guided radiation therapy treatments]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: use of extracorporeal membrane oxygenation (ECMO) in adults in Quebec]
2018     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: use of clinical data from electronic medical records for research and continuous quality improvement in front-line care and services]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: treatment of mitral regurgitation by a percutaneous device with clip (TMVRc)]
2020     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: tomosynthesis and breast cancer: diagnostic evaluation and other uses]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: tisagenlecleucel for the treatment of relapsed or refractory diffuse large B-cell lymphoma]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: tisagenlecleucel for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia]
2018     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: the use of EndoPredict and Prosigna for early invasive breast cancer]
2020     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: the therapeutic value of hyperbaric oxygen (HBO) on children with cerebral palsy]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: the placenta, utility of and indications for the transfer of samples to the anatomical pathology laboratory for analysis]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: The Argus II retinal implant]
2020     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Takhzyro (lanadelumab), notice of inclusion on the Liste des produits du système du sang du Québec]
2018     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: surgical treatment of the esophagus - quality and accessibility in Quebec]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: submission of surgical specimens to the anatomic pathology laboratory: relevance and indications - vascular, cardiovascular and thoracic surgery]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: submission of surgical specimens to the anatomic pathology laboratory: relevance and indications - otolaryngology and oral, maxillofacial and head and neck surgery]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: submission of surgical specimens to the anatomic pathology laboratory: relevance and indications - eye surgery]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: submission of surgical specimens to the anatomic pathology laboratory - relevance and indications - orthopedic surgery and neurosurgery]
2017     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: statins, lipid-lowering agents and cardiovascular risk reduction]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: setting safety and conditions for success of vaginal birth after cesarean]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: revision of criteria for the withholding and termination of resuscitation by paramedics in prehospital setting]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: resuscitation in community opioid overdose ‒ update and complement to INESSS guidance published in 2018 - Cardiopulmonary resuscitation (CPR) in a context of community-based naloxone administration for opioid overdose]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevant practices for promoting hearing health in long-term residential care settings]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevance of using mpMRI for the diagnostic investigation of prostate cancer - mpMRI and prostate cancer diagnosis]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevance of neonatal pulse oximetry screening for critical congenital heart disease]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevance of low-dose computed tomography lung cancer screening]
2017     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevance of introducing a pathogen inactivation process for labile blood products in Quebec]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevance of and indications for submitting surgical specimens to the anatomic pathology laboratory: obstetrics/gynecology and urology]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevance of and indications for submitting surgical specimens to the anatomic pathology laboratory: general surgery, plastic surgery and dermatology]